13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab

Journal article

Peer reviewed

W.J Sandborn, S Vermeire, G D'Haens, J.F Colombel, R.N Fedorak, M.E Spehlmann, M.T Abreu, K Mitchev, C Jamoul and P Rutgeerts

Journal of Crohn's and colitis, Vol.3(1), pp.S8-S9

2009-02

Metrics

7 Record Views

Title: 13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab
Creators: W.J Sandborn
S Vermeire
G D'Haens
J.F Colombel
R.N Fedorak
M.E Spehlmann
M.T Abreu
K Mitchev
C Jamoul
P Rutgeerts
Publication Details: Journal of Crohn's and colitis, Vol.3(1), pp.S8-S9
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Gastroenterology
Language: English
Resource Type: Journal article
Record Identifier: 991031599367102976